What the Science Currently Says About Red Light Therapy

How Red Light Affects Mitochondria

The cleanest way to understand red light therapy is to follow the photon from the skin to the mitochondrion. A 660 nm photon reaches a cell and is absorbed by cytochrome c oxidase, the fourth complex in the mitochondrial respiratory chain. Absorption triggers a cascade... increased electron transport activity, a rise in mitochondrial membrane potential, and enhanced ATP synthesis (Hamblin, 2018; Ravera et al., 2021; De Freitas & Hamblin, 2016).

Alongside ATP, a few other things shift. Nitric oxide is released from its binding site on cytochrome c oxidase, which supports local blood flow. A brief, controlled burst of reactive oxygen species acts as a signaling event rather than a damaging one, activating transcription factors involved in repair and cell survival (Maghfour et al., 2024). Calcium signaling pathways modulate. The result is what one group of authors called a mitochondrial "tune-up" at the molecular level.

It is worth noting that this is not a placebo effect hiding behind a colored bulb. Action spectra... experiments that vary the exact wavelength and measure the response... consistently confirm that red and near-infrared bands map onto the absorption peaks of cytochrome c oxidase. The biology is specific to the wavelength, not to the experience of sitting in warm light (Hamblin, 2018; Salehpour et al., 2018).

Wavelengths and the Therapeutic Window

Most of the useful therapy happens in two bands. Red light, between 620 and 700 nm, with the most effective work clustered around 633 to 660 nm, reaches superficial tissues... skin, surface vasculature, shallow wounds. Near-infrared, 700 to 900 nm and especially 800 to 830 nm, penetrates deeper... bone, muscle, joint, and yes, the brain through the skull, though attenuated (Jeffery et al., 2025; Colombo et al., 2021).

The boundary of this therapeutic window matters. Shorter wavelengths, particularly blue light around 415 nm and UV, do not share the same friendly relationship with mitochondria. Several studies show that blue and UV exposure can reduce ATP production and increase oxidative stress, which is the opposite of what we want (Núñez-Álvarez & Osborne, 2019; Osborne et al., 2017; Lee et al., 2024). Blue light does have legitimate antimicrobial uses, but it is not a tool for mitochondrial support.

"The therapeutic window is roughly 630 to 900 nanometers. Red reaches surface tissue. Near-infrared goes deeper. Outside that window, mitochondria stop cooperating."

Dermatology

STRONG

Dermatology is where red light therapy has its longest and most rigorously studied track record. A 2024 CME review in the Journal of the American Academy of Dermatology covers the mechanism, the parameters, and the current indications at length (Mineroff et al., 2024; Maghfour et al., 2024).

The best-supported indications:

• Acne vulgaris. 633 nm light delivered at modest fluences reduces lesion counts and inflammation (Ablon, 2018; Kennedy, 2023).
• Wound healing (including diabetic ulcers). Red at 630 to 680 nm and NIR at 800 to 830 nm accelerate closure and improve collagen organization (Oyebode et al., 2021; Yadav & Gupta, 2017; Dungel et al., 2023).
• Skin rejuvenation and photoaging. Collagen stimulation and improved skin texture are reproducible, though effect sizes are modest and protocols vary.
• Alopecia. Consistent benefit for androgenetic alopecia with at-home LED caps and laser combs at specific parameters.
• Psoriasis, actinic keratosis, scar reduction. Emerging but supportive data.

Methodological caveat... a 2024 review in PLOS One pointed out that many dermatology studies of LED therapy are underpowered, unblinded, or industry-sponsored. Read individual claims with a discerning eye (Grimes, 2024).

Ophthalmology and Myopia

STRONG MODERATE

Strong for myopia control in children · Moderate for AMD

Repeated low-level red light therapy, typically 635 to 650 nm delivered as two three-minute sessions per day with at least four hours between exposures, is now one of the better-studied interventions for slowing myopia progression in school-age children. Multiple randomized controlled trials and Bayesian network meta-analyses report meaningful reductions in axial elongation and spherical equivalent progression (Jiang et al., 2021; Zhou et al., 2023; Cao et al., 2024; Tang et al., 2023; Zaabaar et al., 2023).

The efficacy signal is strong. The safety conversation is still open. A 2024 paper in Ophthalmic and Physiological Optics flagged that some commercially available devices exceed maximum permissible exposure limits for the retina, and long-term retinal safety data in children is thin (Ostrin & Schill, 2024). This is a field where the science and the marketing are moving at different speeds. If this is relevant to your family, have the conversation with a pediatric ophthalmologist who is following the literature.

For age-related macular degeneration, PBM has a plausible mechanism (restoring mitochondrial function in the retinal pigment epithelium) and some early clinical signals, but larger trials are still needed before we can call it standard of care (Fantaguzzi et al., 2023; Chichan et al., 2025).

Neurology and Cognition

MODERATE

Transcranial photobiomodulation, usually 810 nm NIR light delivered through a helmet or forehead applicator, has been studied for a wide range of neurological conditions. The results are genuinely interesting and not yet definitive.

In animal models, transcranial PBM improves brain mitochondrial function, enhances memory performance, and appears to slow pathology in models of aging, Alzheimer's, and Parkinson's disease (Eells et al., 2004; Salehpour et al., 2017; Bathini et al., 2020). In humans, small pilot studies and case series suggest cognitive benefit after traumatic brain injury and in early neurodegenerative disease, but large confirmatory RCTs are still ahead of us (Nairuz et al., 2024; Salehpour et al., 2018; Johnstone et al., 2016; Shen et al., 2024).

The honest summary... this is one of the most exciting areas of PBM research, and also one where patients should be most cautious about overpromising marketing.

Pain Management

MODERATE STRONG

Moderate to Strong

Red and NIR light have a long history of use for musculoskeletal pain, neuropathic pain, and inflammation. A narrative review in The Journal of Pain summarized the mechanisms... reduced nerve conduction velocity, decreased inflammatory cytokines, and modulation of peripheral pain signaling (Cheng et al., 2021). Clinically, 660 nm is typical for surface pain (arthritic joints, tendinopathy, skin pain), while 810 to 830 nm is used for deeper tissues.

Fluences in the 1 to 6 J/cm² range are most commonly reported. Higher is not better.

Wound Healing

STRONG

Already covered in the dermatology section. Key points repeated briefly... red at 630 to 680 nm, NIR at 800 to 830 nm, consistent evidence for accelerated closure, improved collagen, and enhanced angiogenesis, with particular promise in diabetic and ischemic wounds (Oyebode et al., 2021; Dungel et al., 2014; Dungel et al., 2023).

Muscle Recovery and Performance

MODERATE

For athletes and active patients, the question is usually... does light actually help me recover faster. The answer, based on a growing literature, is "probably yes, modestly, when dosed correctly." PBM stimulates muscle mitochondria to increase ATP production, supports regeneration after exercise-induced damage, and appears to reduce soreness markers (Miejska-Kamińska et al., 2025). Effect sizes in the best trials are real but modest. Dose parameters and timing (pre-exercise versus post-exercise) still vary between studies.

Metabolic Health

EMERGING

One of the more surprising recent findings. A 2024 study from Powner and Jeffery showed that 670 nm light exposure reduced postprandial blood glucose spikes in human subjects, apparently by driving up mitochondrial ATP demand systemically (Powner & Jeffery, 2024). A single study does not make a therapy. But it is a finding that reframes red light as something that may touch metabolism, not just surface tissues. Worth watching closely.

Emerging and Speculative Applications

• Anti-aging and longevity. Early-life red light exposure extended lifespan in C. elegans via ROS-AMPK-driven mitochondrial reprogramming (Zhu et al., 2025). Mechanistically interesting, clinically speculative in humans.
• Reproductive health. A small prospective case series suggested multiwavelength PBM may support female fertility outcomes. Larger trials needed (Phypers et al., 2024).
• Respiratory and post-viral. Early papers proposed PBM as supportive care in severe respiratory infection, including COVID complications. Evidence remains preliminary (Enwemeka et al., 2020).
• Bone and periodontal regeneration. Red (635 nm) and NIR (808 nm) appear to support osteoblast activity and gingival fibroblast viability (Tani et al., 2018; Kocherova et al., 2021).
• Thrombosis and hemostasis. A 2025 paper in Seminars in Thrombosis and Hemostasis reviewed a small but growing body of work. Early (Fan et al., 2025).

Safety and Dosing

Red and near-infrared light therapy is generally very well tolerated. Most adverse events reported in the literature are transient... mild warmth, brief brightness discomfort, very rarely a mild headache. Serious adverse events are rare when devices are used within recommended parameters.

The places to be careful:

1. The biphasic dose response. Typical therapeutic fluences range from 1 to 6 J/cm² per session. Pushing much higher can reduce benefit rather than increase it (Hamblin, 2017; Gupta et al., 2013).
2. Eye exposure. Red light devices marketed for pediatric myopia have raised ocular safety concerns, with some exceeding maximum permissible retinal exposure limits (Ostrin & Schill, 2024). Always use goggles or avoid direct eye exposure unless a device is specifically designed and cleared for ocular use.
3. Photosensitivity. Certain medications (some antibiotics, some chemotherapeutics, some retinoids) increase skin photosensitivity. Talk with a clinician if you are on any of these.
4. Pregnancy. There is no strong evidence of harm, but long-term safety data in pregnancy is limited. Caution is reasonable.
5. Active cancer. The effect of PBM on active tumors is an open research question. Patients with active malignancy should discuss PBM with their oncology team before using it.

Research Gaps and Open Questions

The biggest gaps in the literature, in no particular order:

• Standardized dosimetry across studies. Fluence, irradiance, treatment duration, and device type vary enormously, which makes meta-analysis hard.
• Long-term safety data, especially for pediatric myopia devices and repeated transcranial use.
• Head-to-head comparisons between PBM and standard-of-care for chronic conditions.
• Molecular mechanisms beyond cytochrome c oxidase. Emerging data suggests additional photoacceptors and secondary messengers.
• Larger, independent, placebo-controlled trials in neurology, metabolic health, and reproductive medicine.

The field is moving. This page will be revised as new evidence comes in.